Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NCT06237920 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Urinary Bladder Diseases
Male Urogenital Diseases
Urinary Bladder Neoplasm
Antineoplastics Toxicity

Interventions

DRUG: Nivolumab
DRUG: Relatlimab

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]